Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;8(9):3209-3212.e8.
doi: 10.1016/j.jaip.2020.04.069. Epub 2020 May 15.

Symptom assessment in hypereosinophilic syndrome: Toward development of a patient-reported outcomes tool

Nicholas Kovacs  1 , Katy Benjamin  2 , Nicole Holland-Thomas  3 , Olga Moshkovich  2 , Linda M Nelsen  4 , Hector Ortega  5 , Ethan J Schwartz  2 , Jonathan Steinfeld  4 , Suyong Yun Kirby  6 , Amy Klion  3 , Paneez Khoury  7
Affiliations

Symptom assessment in hypereosinophilic syndrome: Toward development of a patient-reported outcomes tool

Nicholas Kovacs et al. J Allergy Clin Immunol Pract. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement:

Paneez Khoury, Amy Klion, Nick Kovacs, and Nicole Holland-Thomas have nothing to disclose.

Linda Nelsen, Jonathan Steinfeld are employees of and hold stock in GlaxoSmithKline. Hector Ortega and Suyong Yun Kirby were employees of GlaxoSmithKline when this research was conducted.

Figures

Figure 1.
Figure 1.
Symptoms reported by HES patients
Figure 2.
Figure 2.
Patient-reported impact of HES on Social, Cognitive, Emotional and Physical functioning.
See this image and copyright information in PMC

References

    1. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009. December;124(6):1319–25.e3. - PMC - PubMed
    1. Helbig G, Moskwa A, Hus M, Woźniczka K, Wieczorkiewicz A, Dziaczkowska-Suszek J, et al. Heterogeneity among characteristics of hypereosinophilic syndromes. Journal of Allergy and Clinical Immunology. 2010. June;125(6):1399–1401.e2. - PubMed
    1. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. Value Health. 2011. December;14(8):967–77. - PubMed
    1. Guidance for IndustryPatient-Reported Outcome Measures:Use in Medical Product Developmentto Support Labeling Claims [Internet]. FDA; 2009. [cited 2009 Dec 31]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf
    1. Schoepfer AM, Straumann A, Panczak R, Coslovsky M, Kuehni CE, Maurer E, et al. Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis. Gastroenterology. 2014. December;147(6):1255–66.e21. - PMC - PubMed

Publication types

MeSH terms